NewsBenzingaBeam Therapeutics Announces Initial Data From Its Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia; In The 40 Mg Cohort, Two Patients Achieved 15 Hours Of Controlled Fasting; Safety Profile Of... Beam Therapeutics Announces Initial Data From Its Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia; In The 40 Mg Cohort, Two Patients Achieved 15 Hours Of Controlled Fasting; Safety Profile Of... Benzinga 2026.10.27 11:11 (GMT+0) Open on Benzinga Other news IBM Stock Moves Lower: What's Going On? JP Morgan Maintains Overweight on Itau Unibanco Holding, Lowers Price Target to $9 Amazon’s Big Week: First a New James Bond, Then Anthropic’s IPO JP Morgan Maintains Overweight on Allstate, Lowers Price Target to $291 TELUS Shares Rise After Québecor Submits Unsolicited Acquisition Proposal NVIDIA's Leadership Vacuum Hands AMD Its Biggest Opportunity in Years: Analysts